Actively Recruiting
Adverse Childhood Experiences and Premature Vascular Aging in Humans: The Role of SIRT1
Led by Nathaniel Jenkins · Updated on 2025-07-18
30
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how adverse childhood experiences (ACEs) affect the health of blood vessels and increase the risk of future heart disease in young adults. The study focuses on a protein called SIRT1, which helps keep blood vessels healthy, and how its activity is reduced in people with four or more ACEs. By understanding these changes, the study aims to find ways to improve blood vessel function in those affected by early life stress. Participants will take part in a randomized, controlled trial where some will receive a dietary supplement called nicotinamide riboside (NR) for four weeks, taken twice daily at a total dose of 2,000 mg per day. This supplement is being studied for its ability to increase SIRT1 activity by boosting cellular NAD+ levels, potentially improving blood vessel function. Others will receive a placebo with no active ingredient. The study compares young adults with high ACE exposure to those without ACEs, using both cross-sectional and intervention phases. Throughout the study, participants will undergo various tests to measure blood vessel function, SIRT1 levels and activity, inflammation, and oxidative stress before and after the supplementation period. They will complete daily logs to track supplement use, and the research team will monitor changes in vascular health indicators over the four weeks. The total participation period includes baseline assessments, the 4-week supplementation, and follow-up measurements to evaluate the effects of the intervention.
CONDITIONS
Brief Title
ACEs, SIRT1, and Premature Vascular Aging in Humans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 30 years
- ACE score of 0 or 4 and above (Aim 1); ACE score 4 and above for Aim 2
You will not qualify if you...
- Resting arterial blood pressure greater than 140/90 mmHg
- Body mass index 30 kg/m2 or higher and/or unstable weight (more than 2.27 kg change) in the last 6 months
- History of cardiovascular, metabolic, or pulmonary disease
- Use of cardiovascular or metabolic prescription medications
- Use of vasoactive antidepressant drugs such as SSRIs and clonidine
- Currently pregnant or breastfeeding
- Heavy alcohol consumption as per AUDIT screening
- Use of illicit drugs
- Current tobacco use
- Regular vigorous aerobic exercise (greater than 6 METs) more than 4 times per week for over 30 minutes each session
- Use of dietary supplements with antioxidants or habitual use of NSAIDs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants consume either nicotinamide riboside or placebo twice daily for 4 weeks while completing a daily supplementation log to monitor compliance.
1 baseline visit and 1 follow-up visit
Trial Site Locations
Total: 1 location
1
Integrative Laboratory of Applied Physiology and Lifestyle Medicine
Iowa City, Iowa, United States, 52242
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here